UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

European journal of cancer (1990), 2001-12, Vol.37 (18), p.2457-2463

2001

Volltextzugriff (PDF)

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

Haematologica (Roma), 2007-10, Vol.92 (10), p.1399-1406

2007

Volltextzugriff (PDF)

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

Journal of clinical oncology, 1995-02, Vol.13 (2), p.314-322

1995

Volltextzugriff (PDF)

Phase I Trial of Taxotere: Five-Day Schedule

JNCI : Journal of the National Cancer Institute, 1992-12, Vol.84 (23), p.1781-1788

1992

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Oxaliplatin: A Critical Review

Clinical cancer research, 2000-04, Vol.6 (4), p.1205-1218

2000

Volltextzugriff (PDF)

Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 1995-05, Vol.87 (9), p.676-681

1995

Volltextzugriff (PDF)

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group

Annals of oncology, 1994-07, Vol.5 (6), p.527

1994

Volltextzugriff (PDF)

Oxaliplatin loaded PLAGA microspheres:: design of specific release profiles

International journal of pharmaceutics, 2002-08, Vol.242 (1), p.243-246

2002

Volltextzugriff (PDF)

Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat

Anticancer research, 2002-11, Vol.22 (6C), p.4199

2002

Volltextzugriff (PDF)

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

Journal of clinical oncology, 1994-07, Vol.12 (7), p.1458-1467

1994

Volltextzugriff (PDF)

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

Journal of clinical oncology, 1993-05, Vol.11 (5), p.950-958

1993

Volltextzugriff (PDF)

Phase i study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

Leukemia, 2000-12, Vol.14 (12), p.2085-2094

2000

Volltextzugriff (PDF)

Molecular determinants of the cytotoxicity of platinum compounds: The contribution of in silico research

Cancer research (Chicago, Ill.), 2004, Vol.64 (1), p.356-362

2004

Volltextzugriff (PDF)

Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y

Journal of neuro-oncology, 2004-03, Vol.67 (1-2), p.65-73

2004

Volltextzugriff (PDF)

Current status of Taxotere (docetaxel) as a new treatment in breast cancer

Breast cancer research and treatment, 1995, Vol.33 (1), p.39-46

1995

Volltextzugriff (PDF)

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group

European journal of cancer (1990), 1994, Vol.30 (8), p.1064-1067

1994

Volltextzugriff (PDF)

Oxaliplatin loaded PLAGA microspheres

International journal of pharmaceutics, 2002-08, Vol.242 (1-2), p.243-246

2002

Volltextzugriff (PDF)

IN VIVO ADMINISTRATION OF RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CORRECTS ACQUIRED NEUTROPHIL FUNCTION DEFICIENCY ASSOCIATION WITH CHRONIC GRAFT‐VERSUS‐HOST DISEASE

British journal of haematology, 1993-01, Vol.83 (1), p.169-170

1993

Volltextzugriff (PDF)

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors

Anti-cancer drugs, 1999-11, Vol.10 (10), p.889-894

1999

Volltextzugriff (PDF)

Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia

Cancer chemotherapy and pharmacology, 1978, Vol.1 (4), p.259

1978

Volltextzugriff (PDF)

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients

Anti-cancer drugs, 1996-02, Vol.7 (2), p.166-174

1996

Volltextzugriff (PDF)

Effects Of Different Schedules Of Oxaliplatin Treatment On The Peripheral Nervous System And The Auditory Pathway In The Rat

Journal of the peripheral nervous system, 2001-03, Vol.6 (1), p.44-44

2001

Volltextzugriff (PDF)

ACLACINOMYCIN A IN ACUTE LEUKÆMIAS AND LYMPHOMAS

The Lancet (British edition), 1979-08, Vol.314 (8137), p.310-311

1979

Volltextzugriff (PDF)

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

Cancer chemotherapy and pharmacology, 1979-01, Vol.2 (4), p.247-255

1979

Volltextzugriff (PDF)

Vindesine: a new vinca alkaloid

Recent results in cancer research, 1980, Vol.74, p.91

1980

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(42)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(25)
Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Oncology
(21)
Female
(19)
Adult
(17)
Biological And Medical Sciences
(17)
Medical Sciences
(17)
Middle Aged
(15)
Pharmacology. Drug Treatments
(15)
Aged
(13)
Antineoplastic Agents
(13)
Male
(13)
Chemotherapy
(11)
Neoplasms - Drug Therapy
(8)
Paclitaxel - Analogs & Derivatives
(8)
Taxoids
(8)
Paclitaxel - Adverse Effects
(7)
Docetaxel
(6)
Paclitaxel - Administration & Dosage
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

Phase I Trial of Taxotere: Five-Day Schedule

Clinical Pharmacokinetics of Oxaliplatin: A Critical Review

Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group

Oxaliplatin loaded PLAGA microspheres:: design of specific release profiles

Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion

Phase i study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

Molecular determinants of the cytotoxicity of platinum compounds: The contribution of in silico research

Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y

Current status of Taxotere (docetaxel) as a new treatment in breast cancer

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC early clinical trials group

Oxaliplatin loaded PLAGA microspheres

IN VIVO ADMINISTRATION OF RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR CORRECTS ACQUIRED NEUTROPHIL FUNCTION DEFICIENCY ASSOCIATION WITH CHRONIC GRAFT‐VERSUS‐HOST DISEASE

Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors

Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients

Effects Of Different Schedules Of Oxaliplatin Treatment On The Peripheral Nervous System And The Auditory Pathway In The Rat

ACLACINOMYCIN A IN ACUTE LEUKÆMIAS AND LYMPHOMAS

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

Vindesine: a new vinca alkaloid

Suchergebnisse filtern